Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health

Michael T. Lotze, Ena Wang, Francesco M. Marincola, Nabil Hanna, Peter J. Bugelski, Christine A. Burns, George Coukos, Nitin Damle, Tony E. Godfrey, W. Martin Howell, Monica C. Panelli, Michael A. Perricone, Emanuel F. Petricoin, Guido Sauter, Carmen Scheibenbogen, Steven C. Shivers, D. Lansing Taylor, John N. Weinstein, Theresa L. Whiteside

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor. We distinguish this from immunologic monitoring in the sense that it is primarily a measure of the tumor burden as opposed to the immune response to it. Recommendations for intensive investigation and targeted funding to enable such strategies were developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies.

Original languageEnglish
Pages (from-to)79-119
Number of pages41
JournalJournal of Immunotherapy
Volume28
Issue number2
Publication statusPublished - Mar 2005
Externally publishedYes

Fingerprint

National Institutes of Health (U.S.)
Tumor Biomarkers
Education
Neoplasms
Immunologic Monitoring
Molecular Targeted Therapy
Biological Therapy
Tumor Burden
Proteomics
Flow Cytometry
Necrosis
Therapeutics
Lymph Nodes
Immunohistochemistry
T-Lymphocytes
Polymerase Chain Reaction

Keywords

  • Biologic therapy
  • Biomarkers
  • Cancer
  • Cytokines
  • Genetic polymorphism
  • Genomics
  • High-content screen
  • Immune infiltration
  • Immune response
  • Immune therapy
  • Immunohistochemistry
  • Microarrays
  • Proteomics
  • Surrogates
  • Transcription analysis
  • Tumor necrosis

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology
  • Pharmacology
  • Cancer Research

Cite this

Workshop on cancer biometrics : Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health. / Lotze, Michael T.; Wang, Ena; Marincola, Francesco M.; Hanna, Nabil; Bugelski, Peter J.; Burns, Christine A.; Coukos, George; Damle, Nitin; Godfrey, Tony E.; Howell, W. Martin; Panelli, Monica C.; Perricone, Michael A.; Petricoin, Emanuel F.; Sauter, Guido; Scheibenbogen, Carmen; Shivers, Steven C.; Taylor, D. Lansing; Weinstein, John N.; Whiteside, Theresa L.

In: Journal of Immunotherapy, Vol. 28, No. 2, 03.2005, p. 79-119.

Research output: Contribution to journalArticle

Lotze, MT, Wang, E, Marincola, FM, Hanna, N, Bugelski, PJ, Burns, CA, Coukos, G, Damle, N, Godfrey, TE, Howell, WM, Panelli, MC, Perricone, MA, Petricoin, EF, Sauter, G, Scheibenbogen, C, Shivers, SC, Taylor, DL, Weinstein, JN & Whiteside, TL 2005, 'Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health', Journal of Immunotherapy, vol. 28, no. 2, pp. 79-119.
Lotze, Michael T. ; Wang, Ena ; Marincola, Francesco M. ; Hanna, Nabil ; Bugelski, Peter J. ; Burns, Christine A. ; Coukos, George ; Damle, Nitin ; Godfrey, Tony E. ; Howell, W. Martin ; Panelli, Monica C. ; Perricone, Michael A. ; Petricoin, Emanuel F. ; Sauter, Guido ; Scheibenbogen, Carmen ; Shivers, Steven C. ; Taylor, D. Lansing ; Weinstein, John N. ; Whiteside, Theresa L. / Workshop on cancer biometrics : Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health. In: Journal of Immunotherapy. 2005 ; Vol. 28, No. 2. pp. 79-119.
@article{354446b40edb4452859f45cf6c5fa6c9,
title = "Workshop on cancer biometrics: Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health",
abstract = "The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor. We distinguish this from immunologic monitoring in the sense that it is primarily a measure of the tumor burden as opposed to the immune response to it. Recommendations for intensive investigation and targeted funding to enable such strategies were developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies.",
keywords = "Biologic therapy, Biomarkers, Cancer, Cytokines, Genetic polymorphism, Genomics, High-content screen, Immune infiltration, Immune response, Immune therapy, Immunohistochemistry, Microarrays, Proteomics, Surrogates, Transcription analysis, Tumor necrosis",
author = "Lotze, {Michael T.} and Ena Wang and Marincola, {Francesco M.} and Nabil Hanna and Bugelski, {Peter J.} and Burns, {Christine A.} and George Coukos and Nitin Damle and Godfrey, {Tony E.} and Howell, {W. Martin} and Panelli, {Monica C.} and Perricone, {Michael A.} and Petricoin, {Emanuel F.} and Guido Sauter and Carmen Scheibenbogen and Shivers, {Steven C.} and Taylor, {D. Lansing} and Weinstein, {John N.} and Whiteside, {Theresa L.}",
year = "2005",
month = "3",
language = "English",
volume = "28",
pages = "79--119",
journal = "Journal of Immunotherapy",
issn = "1524-9557",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Workshop on cancer biometrics

T2 - Identifying biomarkers and surrogates of cancer in patients - A meeting held at the masur auditorium, national institutes of health

AU - Lotze, Michael T.

AU - Wang, Ena

AU - Marincola, Francesco M.

AU - Hanna, Nabil

AU - Bugelski, Peter J.

AU - Burns, Christine A.

AU - Coukos, George

AU - Damle, Nitin

AU - Godfrey, Tony E.

AU - Howell, W. Martin

AU - Panelli, Monica C.

AU - Perricone, Michael A.

AU - Petricoin, Emanuel F.

AU - Sauter, Guido

AU - Scheibenbogen, Carmen

AU - Shivers, Steven C.

AU - Taylor, D. Lansing

AU - Weinstein, John N.

AU - Whiteside, Theresa L.

PY - 2005/3

Y1 - 2005/3

N2 - The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor. We distinguish this from immunologic monitoring in the sense that it is primarily a measure of the tumor burden as opposed to the immune response to it. Recommendations for intensive investigation and targeted funding to enable such strategies were developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies.

AB - The current excitement about molecular targeted therapies has driven much of the recent dialog in cancer diagnosis and treatment. Particularly in the biologic therapy of cancer, identifiable antigenic T-cell targets restricted by MHC molecules and the related novel stress molecules such as MICA/B and Letal allow a degree of precision previously unknown in cancer therapy. We have previously held workshops on immunologic monitoring and angiogenesis monitoring. This workshop was designed to discuss the state of the art in identification of biomarkers and surrogates of tumor in patients with cancer, with particular emphasis on assays within the blood and tumor. We distinguish this from immunologic monitoring in the sense that it is primarily a measure of the tumor burden as opposed to the immune response to it. Recommendations for intensive investigation and targeted funding to enable such strategies were developed in seven areas: genomic analysis; detection of molecular markers in peripheral blood and lymph node by tumor capture and RT-PCR; serum, plasma, and tumor proteomics; immune polymorphisms; high content screening using flow and imaging cytometry; immunohistochemistry and tissue microarrays; and assessment of immune infiltrate and necrosis in tumors. Concrete recommendations for current application and enabling further development in cancer biometrics are summarized. This will allow a more informed, rapid, and accurate assessment of novel cancer therapies.

KW - Biologic therapy

KW - Biomarkers

KW - Cancer

KW - Cytokines

KW - Genetic polymorphism

KW - Genomics

KW - High-content screen

KW - Immune infiltration

KW - Immune response

KW - Immune therapy

KW - Immunohistochemistry

KW - Microarrays

KW - Proteomics

KW - Surrogates

KW - Transcription analysis

KW - Tumor necrosis

UR - http://www.scopus.com/inward/record.url?scp=20044383193&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20044383193&partnerID=8YFLogxK

M3 - Article

C2 - 15725954

AN - SCOPUS:20044383193

VL - 28

SP - 79

EP - 119

JO - Journal of Immunotherapy

JF - Journal of Immunotherapy

SN - 1524-9557

IS - 2

ER -